Abbvie Inc Stock Fair Value Calculation – ABBVIE INC Anticipates Revenues to Increase in Glaucoma Aqueous Shunt Market by 2030

☀️Trending News

ABBVIE INC ($NYSE:ABBV) is a global, research-based biopharmaceutical company that strives to discover and develop advanced therapies for diseases such as cancer, neurological disorders, and chronic illnesses. ABBVIE Inc. is currently expecting to witness an upsurge in the Glaucoma Aqueous Shunt Market by 2030. Glaucoma is an eye disorder that causes progressive damage to the optic nerve due to increased intraocular pressure (IOP). An aqueous shunt device is an implantable device that relieves the IOP by diverting aqueous humor from the intraocular space to another part of the eye. The availability of newer more efficient devices has improved patient outcomes by reducing the need for repeat surgeries and long-term treatments. Given the projected growth in the glaucoma aqueous shunt market, ABBVIE Inc. is preparing itself to capitalize on this opportunity by investing in research and development to develop innovative solutions for ophthalmic diseases.

The company is actively involved in collaborations with medical device companies, academic institutions, and medical centers to create better products. ABBVIE Inc. is also working on strengthening its portfolio of glaucoma-related products and services. The company is well positioned to drive the development of breakthrough therapies that will improve outcomes for patients suffering from glaucoma. ABBVIE Inc. is confident that their investments and collaborations will enable them to exceed their expectations and expand their operations in the glaucoma aqueous shunt market.

Earnings

ABBVIE INC released its earning report of FY2023 Q1 ending March 31 2023, stating that the company earned 12.22B USD in total revenue and 0.24B USD in net income. Compared to the same period of last year, total revenue decreased by 9.7%, and net income decreased by 94.7%. Furthermore, ABBVIE INC’s total revenue has decreased from 13.01B USD to 12.22B USD in the last three years. The market has grown significantly in recent years due to the increasing prevalence of glaucoma and the growing demand for minimally invasive treatments.

With the help of its drug portfolio, ABBVIE INC is well-positioned to capitalize on this growing market. The company is also focused on developing new treatments for glaucoma, which it hopes will drive further revenue growth in the near future.

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Abbvie Inc. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Abbvie Inc. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Abbvie Inc. More…

Key Ratios Snapshot

Some of the financial key ratios for Abbvie Inc are shown below. More…

Share Price

The announcement sent ABBVIE INC stock down 1.8%, from a prior closing price of $141.2 to $138.6. This is a significant indication of investor sentiment, as the company is now expecting to increase its share in the glaucoma aqueous shunt market and surpass its competitors. With its new strategy in place, ABBVIE INC looks to remain on track with its long-term goals and deliver positive returns for its shareholders. Live Quote…

Analysis – Abbvie Inc Stock Fair Value Calculation

At GoodWhale, we have carried out an analysis of ABBVIE INC‘s fundamentals. Our proprietary Valuation Line has calculated the fair value of an ABBVIE INC share to be around $134.8. Currently, ABBVIE INC stock is trading at $138.6, indicating a fair price that is slightly overvalued by 2.8%. More…

Peers

AbbVie Inc is a global, research-based biopharmaceutical company formed in 2013. AbbVie combines the focus and passion of a leading-edge biotech with the experience and breadth of a long-established pharmaceutical leader to develop and market advanced therapies that address some of the world’s most complex and serious diseases.

Kwang Dong Pharmaceutical Co Ltd, Jiangsu Hengrui Pharmaceuticals Co Ltd, Vivesto AB are all competitors of AbbVie Inc.

– Kwang Dong Pharmaceutical Co Ltd ($KOSE:009290)

Kwang Dong Pharmaceutical Co Ltd is a South Korean company that manufactures and sells pharmaceutical products. The company has a market cap of 233.75 billion as of 2022 and a return on equity of 19.33%. Kwang Dong Pharmaceutical Co Ltd manufactures a wide range of pharmaceutical products, including antibiotics, anti-inflammatory drugs, and cardiovascular drugs. The company also has a research and development department that is responsible for developing new drugs and formulations.

– Jiangsu Hengrui Pharmaceuticals Co Ltd ($SHSE:600276)

Jiangsu Hengrui Pharmaceutical Co., Ltd. is a Chinese pharmaceutical company that engages in the research, development, manufacture, and sale of chemical and biological drugs in China and internationally. The company has a market cap of 248.78 billion as of 2022 and a return on equity of 6.72%. Jiangsu Hengrui Pharmaceutical Co., Ltd. is headquartered in Lianyungang, China.

– Vivesto AB ($OTCPK:OASMY)

Vivesto AB is a Swedish company that provides financial technology solutions. The company has a market capitalization of 32.61 million as of 2022 and a return on equity of -9.39%. Vivesto’s products and services include online banking, mobile banking, and payments solutions. The company serves retail, corporate, and institutional clients.

Summary

The company has a diversified portfolio of drugs such as Humira, Imbruvica and Venclexta, as well as a pipeline of new medicines in development. Its long-term prospects look positive, with analysts expecting revenues to continue to grow and earnings to increase even further over the next decade. ABBVIE Inc is a solid choice for investors looking for stable, reliable returns over the long term.